Search research articles
Contact Us
Filters
Showing results (51-60 of 70) with videos related to
Page
of 7
Sort By:
The Journal of Clinical Endocrinology and Metabolism
|
February 28, 2019
Attenuation of Weight Loss Through Improved Antilipolytic Effect in Adipose Tissue Via the SGLT2 Inhibitor Tofogliflozin
Akihiro Yoshida, Yasuhiro Matsubayashi, Toshiaki Nojima, et al.
Diabetes, Obesity & Metabolism
|
January 28, 2020
Association of increased hepatic insulin clearance and change in serum triglycerides or β-hydroxybutyrate concentration via the sodium/glucose-cotransporter 2 inhibitor tofogliflozin
Yasuhiro Matsubayashi, Akihiro Yoshida, Hideki Suganami, et al.
Pharmaceutical Statistics
|
February 20, 2020
Restricted mean survival time as a summary measure of time-to-event outcome
Takahiro Hasegawa, Saori Misawa, Shintaro Nakagawa, et al.
Journal of Diabetes Investigation
|
March 22, 2021
Dipeptidyl peptidase-4 inhibitor, anagliptin, alters hepatic insulin clearance in relation to the glycemic status in Japanese individuals with type 2 diabetes
Takahiro Abe, Yasuhiro Matsubayashi, Sayaka Muragishi, et al.
Microbes and Infection
|
May 26, 2004
Regional distribution of two related Northeast Asian genotypes of JC virus, CY-a and -b: implications for the dispersal of Northeast Asians
Huai-Ying Zheng, Pengyun Zhao, Hideki Suganami, et al.
Alimentary Pharmacology & Therapeutics
|
September 16, 2021
Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), versus placebo in patients with non-alcoholic fatty liver disease
Atsushi Nakajima, Yuichiro Eguchi, Masato Yoneda, et al.
Diabetes, Obesity & Metabolism
|
March 26, 2021
Association of estimated plasma volume and weight loss after long-term administration and subsequent discontinuation of the sodium-glucose cotransporter-2 inhibitor tofogliflozin
Yasuhiro Matsubayashi, Akihiro Yoshida, Hideki Suganami, et al.
Cardiovascular Diabetology
|
April 1, 2014
Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study
Kohei Kaku, Hirotaka Watada, Yasuhiko Iwamoto, et al.
Expert Opinion on Pharmacotherapy
|
February 12, 2014
Long-term safety and efficacy of tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, as monotherapy or in combination with other oral antidiabetic agents in Japanese patients with type 2 diabetes mellitus: multicenter, open-label, randomized controlled trials
Yukio Tanizawa, Kohei Kaku, Eiichi Araki, et al.
Journal of Clinical Lipidology
|
February 24, 2026
Efficacy for LDL-C-lowering and safety of pemafibrate extended-release formulation in patients with statin-intolerant hypercholesterolemia: A phase 3 multicenter, randomized, double-blind, placebo-controlled, parallel-group trial
Shizuya Yamashita, Eiichi Araki, Hidenori Arai, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 70) with videos related to
Sort By:
Page
of 7
The Journal of Clinical Endocrinology and Metabolism
|
February 28, 2019
Attenuation of Weight Loss Through Improved Antilipolytic Effect in Adipose Tissue Via the SGLT2 Inhibitor Tofogliflozin
Akihiro Yoshida, Yasuhiro Matsubayashi, Toshiaki Nojima, et al.
Diabetes, Obesity & Metabolism
|
January 28, 2020
Association of increased hepatic insulin clearance and change in serum triglycerides or β-hydroxybutyrate concentration via the sodium/glucose-cotransporter 2 inhibitor tofogliflozin
Yasuhiro Matsubayashi, Akihiro Yoshida, Hideki Suganami, et al.
Pharmaceutical Statistics
|
February 20, 2020
Restricted mean survival time as a summary measure of time-to-event outcome
Takahiro Hasegawa, Saori Misawa, Shintaro Nakagawa, et al.
Journal of Diabetes Investigation
|
March 22, 2021
Dipeptidyl peptidase-4 inhibitor, anagliptin, alters hepatic insulin clearance in relation to the glycemic status in Japanese individuals with type 2 diabetes
Takahiro Abe, Yasuhiro Matsubayashi, Sayaka Muragishi, et al.
Microbes and Infection
|
May 26, 2004
Regional distribution of two related Northeast Asian genotypes of JC virus, CY-a and -b: implications for the dispersal of Northeast Asians
Huai-Ying Zheng, Pengyun Zhao, Hideki Suganami, et al.
Alimentary Pharmacology & Therapeutics
|
September 16, 2021
Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), versus placebo in patients with non-alcoholic fatty liver disease
Atsushi Nakajima, Yuichiro Eguchi, Masato Yoneda, et al.
Diabetes, Obesity & Metabolism
|
March 26, 2021
Association of estimated plasma volume and weight loss after long-term administration and subsequent discontinuation of the sodium-glucose cotransporter-2 inhibitor tofogliflozin
Yasuhiro Matsubayashi, Akihiro Yoshida, Hideki Suganami, et al.
Cardiovascular Diabetology
|
April 1, 2014
Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study
Kohei Kaku, Hirotaka Watada, Yasuhiko Iwamoto, et al.
Expert Opinion on Pharmacotherapy
|
February 12, 2014
Long-term safety and efficacy of tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, as monotherapy or in combination with other oral antidiabetic agents in Japanese patients with type 2 diabetes mellitus: multicenter, open-label, randomized controlled trials
Yukio Tanizawa, Kohei Kaku, Eiichi Araki, et al.
Journal of Clinical Lipidology
|
February 24, 2026
Efficacy for LDL-C-lowering and safety of pemafibrate extended-release formulation in patients with statin-intolerant hypercholesterolemia: A phase 3 multicenter, randomized, double-blind, placebo-controlled, parallel-group trial
Shizuya Yamashita, Eiichi Araki, Hidenori Arai, et al.
Page
of 7